Carbowemb 450mg\45ml Injection

Carbowemb 450mg/ 45ml Injection is an anti-cancer medication used in the treatment of ovarian and non-small cell lung cancer (NSCLC). Its active ingredient is Carboplatin Injection, which belongs to the class of drug family known as platinum-based chemotherapeutic agents.

It works by damaging the DNA of cancer cells, preventing them from growing and causing them to die. The correct dosage and duration is recommended by the healthcare provider only, strict medical attention is required while taking the medications.​

• Ovarian cancer and non small cell lung cancer

Every medication has certain side effects, some may resolve on their own and some need proper medical attention to recover. Consult the doctor if any of these symptoms persist:

• Loss of taste, diarrhea
• Constipation
• Hair loss
• Skin rashes
• Itchiness

• Kidney problems
• Hearing problems
• Fever, chills

• Reduced number of red blood cells (anemia)
• Allergic reactions
• Abnormal bruises

• Doctors prescribed Carbowemb 450mg/ 45ml Injection at the fixed time everyday to enhance the effectiveness of the medication. Taking in the wrong way or taking too much may increase the side effects.
• It may take several weeks or months to show the full benefit of the treatment. The dose adjustment must be administered only by the healthcare provider.​
  

• Carbowemb 450mg Injection is a platinum based chemotherapy drug. It bind to the DNA of cancer cells, creating cross-links that prevent the DNA from functioning properly. The drug damages the DNA of cancer cells in the body.
• It works by blocking the cancer formation pathway and slowing the disease progression. It manages the cancer cells from multiplying and spread to other body parts. It is usually given under medical supervision to ensure safe and effective treatment.​
  

• Schmack, I., Hubbard, G. B., Kang, S. J., Aaberg Jr, T. M., & Grossniklaus, H. E. (2006). Ischemic necrosis and atrophy of the optic nerve after periocular carboplatin injection for intraocular retinoblastoma. American journal of ophthalmology, 142(2), 310-315. https://pubmed.ncbi.nlm.nih.gov/16876514/
• Go, R. S., & Adjei, A. A. (1999). Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. Journal of Clinical Oncology, 17(1), 409-409. https://pubmed.ncbi.nlm.nih.gov/10458260/
• Elferink, F., Van der Vijgh, W. J. F., Klein, I., Vermorken, J. B., Gall, H. E., & Pinedo, H. M. (1987). Pharmacokinetics of Carboplatin After Iv Administration 1, 2. Cancer treatment reports, 71(12), 1231. https://pubmed.ncbi.nlm.nih.gov/3319135/
• Douple, E. B., Richmond, R. C., O'Hara, J. A., & Coughlin, C. T. (1985). Carboplatin as a potentiator of radiation therapy. Cancer treatment reviews, 12, 111-124. https://pubmed.ncbi.nlm.nih.gov/3910216/
• Wagstaff, A. J., Ward, A., Benfield, P., & Heel, R. C. (1989). Carboplatin: a preliminary review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the treatment of cancer. Drugs, 37(2), 162-190. https://pubmed.ncbi.nlm.nih.gov/2649354/​